Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
This trial is active, not recruiting.
|Condition||b-chronic lymphocytic leukemia|
|Treatments||pentostatin, rituximab, cyclophosphamide|
|Start date||July 2002|
|End date||November 2013|
|Trial size||28 participants|
|Trial identifier||NCT00201721, NCT00423423, OSU-0143|
This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
To assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide.
time frame: up to 5 years
To monitor and assess toxicity of this regimen.
time frame: up to 5 years
Male or female participants at least 18 years old.
Inclusion Criteria: - Diagnosis of B-CLL (no mantle cell) - Must have active disease - Age >=18 yo - ECOG 0-3 - No radiation or surgery <4 weeks Exclusion Criteria: - Any of the following comorbid conditions: - New York Heart Association Class III or IV heart disease - Recent myocardial infarction (<1 month) - Uncontrolled infection - Active infection with the human immunodeficiency virus (HIV/AIDS) as further severe immunosuppression with this regimen may occur. - Pregnant or nursing women - Men or women of child bearing potential must use adequate contraception. - Active primary malignancy requiring treatment or limits survival to ≤2 years. - Any radiation therapy ≤4 weeks prior to study entry. - Any major surgery ≤4 weeks prior to study entry.
|Official title||Phase II Trial of Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)|
|Principal investigator||John Byrd|
|Description||Rationale: Research indicates that both cyclophosphamide and pentostatin work synergistically against cancer cells and have a high response rate against chronic lymphocytic leukemia (CLL) without creating severe side effects in patients. In addition, studies have shown that rituximab, a therapy that targets the immune system, has the highest efficacy against CLL and the lowest toxicity rate when compared with other immunotherapy drugs. Studies also show that rituximab enhances the efficacy of the chemotherapy agents cyclophosphamide and pentostatin. This study offers the combination of immunotherapy with two promising chemotherapy agents against CLL. Purpose: This study is evaluating the efficacy and safety of combination treatment with cyclophosphamide, pentostatin, and rituximab in patients with CLL. Several tests evaluating the genetic and molecular components of CLL will also be performed. Some of these tests will be conducted before, during, and after treatments to assess changes resulting from the study drugs. Each patient's outcome will be assessed in relation to various aspects of their genes.|
Call for more information